Invivyd, Inc. (IVVD) stock
IVVDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 9/3048% below fair value
$0.51−0.03 (-4.67%)
Close on Nov 17, 2026Market cap $151.09MP/E –Yield –
Invivyd operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Invivyd's operating cash flow for the twelve months ending Jun 30, 2026 was -$108.42M. For fiscal 2025 it was -$58.14M. The highest annual figure on record is -$58.14M in fiscal 2025.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$58.14M | – |
| FY2024 | Dec 31, 2024 | -$170.49M | – |
| FY2023 | Dec 31, 2023 | -$173.16M | – |
| FY2022 | Dec 31, 2022 | -$219.99M | – |
| FY2021 | Dec 31, 2021 | -$184.74M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$43.01M | – |
| Q1 FY2026 | Mar 31, 2026 | -$41.71M | – |
| Q4 FY2025 | Dec 31, 2025 | -$15.46M | – |
| Q3 FY2025 | Sep 30, 2025 | -$8.25M | – |
| Q2 FY2025 | Jun 30, 2025 | -$13.30M | – |
| Q1 FY2025 | Mar 31, 2025 | -$21.13M | – |
| Q4 FY2024 | Dec 31, 2024 | -$37.61M | – |
| Q3 FY2024 | Sep 30, 2024 | -$41.07M | – |
| Q2 FY2024 | Jun 30, 2024 | -$41.60M | – |
| Q1 FY2024 | Mar 31, 2024 | -$50.21M | – |
| Q4 FY2023 | Dec 31, 2023 | -$59.24M | – |
| Q3 FY2023 | Sep 30, 2023 | -$35.35M | – |
| Q2 FY2023 | Jun 30, 2023 | -$37.39M | – |
| Q1 FY2023 | Mar 31, 2023 | -$41.18M | – |
| Q4 FY2022 | Dec 31, 2022 | -$47.40M | – |
| Q3 FY2022 | Sep 30, 2022 | -$56.14M | – |
| Q2 FY2022 | Jun 30, 2022 | -$57.39M | – |
| Q1 FY2022 | Mar 31, 2022 | -$59.05M | – |
| Q4 FY2021 | Dec 31, 2021 | -$73.21M | – |
| Q3 FY2021 | Sep 30, 2021 | -$54.21M | – |
| Q2 FY2021 | Jun 30, 2021 | -$33.57M | – |
| Q1 FY2021 | Mar 31, 2021 | -$23.74M | – |
See a number that looks wrong?